Arbutus Biopharma Corporation ABUS Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's change in AP?
- Arbutus Biopharma Corporation (ABUS) reported change in AP of -$985K in Q1 2026.
- How has Arbutus Biopharma Corporation's change in AP changed year-over-year?
- Arbutus Biopharma Corporation's change in AP decreased by 121.7% year-over-year, from $4.55M to -$985K.
- What is the long-term trend for Arbutus Biopharma Corporation's change in AP?
- Over 2 years (2021 to 2024), Arbutus Biopharma Corporation's change in AP has grown at a 19.5% compound annual growth rate (CAGR), from $1.91M to -$2.73M.
- What does change in AP mean?
- Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.